Breaking Finance News

Concordia International Corp (NASDAQ:CXRX) has been downgraded to Buy in a statement by Canaccord Genuity earlier today.

Only yesterday Concordia International Corp (NASDAQ:CXRX) traded 18.31% lower at $5.40. Concordia International Corp’s 50-day moving average is $10.95 and its two hundred day average is $22.25. The last close is down 75.74% from the two hundred day moving average, compared with the S&P 500 which has fallen -0.01% over the date range. 6,908,746 shares of Concordia International Corp were exchanged, up from ann avg. trading volume of 881,448.

Canaccord Genuity has downgraded Concordia International Corp(NASDAQ:CXRX) to Buy in a statement released 9/16/2016.

Recent Performance Graph:

Concordia International Corp (NASDAQ:CXRX)

A total of 10 brokers have released a ratings update on Concordia International Corp. Zero rate the company a strong buy, 0 rate the stock a buy, 0 analysts rate the stock a hold, 0 rate the company to underperform, and finally 0 analystsrate the company as sell with a one year target of $52.01

Concordia International Corp has a 52 week low of $4.80 and a one-year high of $76.10. The company’s market cap is currently $0.0.

Brief Synopsis On Concordia International Corp (NASDAQ:CXRX)

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, and includes centralized costs incurred by the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.